16 completed, 14 recruiting, 9 unknown, 6 not yet recruiting. 27 Phase 1, 27 Phase 2, 9 Not applicable, 1 Early Phase 1, 1 Phase 3.
Follow CRC: new trials by email Literature Review of CRC trials Research Report on CRC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer) | Not applicable | Not yet recruiting | Natera, Inc. | 920 | 2027-01-01 | 2026-10-27 |
| A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging) - NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 | Recruiting | Aktis Oncology, Inc. | 152 | 2026-11-01 | 2026-10-22 |
| Colon Health Champion Program Intervention Arm: Colon Health Champions (CHC) Program - Colorectal Cancer, CRC | Not applicable | Not yet recruiting | Virginia Commonwealth University | 29 | 2026-09-10 | 2026-09-01 |
| A Study of a Urine Test to Detect Colorectal Cancer 3-metabolite biosensor - Colorectal Cancer, Precancerous Polyp | Recruiting | Memorial Sloan Kettering Cancer Center | 210 | 2026-06-11 | 2026-06-15 | |
| Noninvasive Early Diagnosis of Colorectal Cancer Using Odor-Targeted Capture, Point-of-Care Testing, and Intelligent Analysis CRC, Precancerous Condition | Not yet recruiting | Beijing University of Chinese Medicine | 453 | 2026-06-10 | 2026-06-02 | |
| Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM SBRT, PD-1 Antibody, H101 - CRC, Liver Metastasis Colon Cancer | Phase 2 | Not yet recruiting | Jun Huang | 114 | 2026-06-01 | 2026-04-28 |
| Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors Daraxonrasib, Elironrasib, Zoldonrasib - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 370 | 2026-01-30 | 2026-08-03 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer CBI-1214 - Colorectal Cancer, Colorectal Cancer (CRC) | Phase 1 | Recruiting | Cartography Biosciences | 80 | 2026-01-15 | 2026-08-26 |
| Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors RMC-5127, daraxonrasib, cetuximab - Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1 | Recruiting | Revolution Medicines, Inc. | 574 | 2026-01-08 | 2026-09-17 |
| A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin, Cohort 2: HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin, Cohort 3: HS-20110+Bevacizumab+Oxaliplatin+Capecitabine - CRC | Phase 1 / Phase 2 | Recruiting | Hansoh BioMedical R&D Company | 502 | 2025-12-22 | 2026-05-01 |
| A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression A2B395, xT CDx with HLA-LOH assay - Solid Tumor, Adult, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | A2 Biotherapeutics Inc. | 240 | 2025-05-22 | 2025-09-09 |
| The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer HCB101, Bevacizumab, Cetuximab (Erbitux) - CRC | Phase 1 / Phase 2 | Recruiting | Chang Gung Memorial Hospital | 40 | 2025-05-14 | 2025-10-02 |
| Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin - Colorectal Cancer, CRC | Phase 2 | Recruiting | Virginia Commonwealth University | 97 | 2025-03-07 | 2026-08-18 |
| First in Human Study of TUB-030 in Patients With Advanced Solid Tumors TUB-030 - Advanced Solid Tumors, HNSCC | Phase 1 / Phase 2 | Recruiting | Gilead Sciences | 250 | 2024-12-13 | 2026-09-11 |
| Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer Ivosidenib (AK112) - CRC, MSS | Phase 2 | Not yet recruiting | Fudan University | 36 | 2024-11-01 | 2024-09-19 |
| Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM Candonilimab (AK104), Regorafenib - CRC | Phase 2 | Unknown | Jin-hong Chen | 44 | 2024-07-11 | 2024-07-30 |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors RMC-6236, mFOLFOX6 regimen, bevacizumab - Colorectal Cancer, CRC | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 1130 | 2024-05-24 | 2026-09-22 |
| A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression A2B694, A2B543, xT CDx with HLA-LOH Assay - Solid Tumor, Adult, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | A2 Biotherapeutics Inc. | 474 | 2024-04-03 | 2026-06-12 |
| A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody - Solid Tumor, HNSCC | Phase 1 | Recruiting | SparX Biotech(Jiangsu) Co., Ltd. | 232 | 2024-03-20 | 2024-09-24 |
| Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation Onvansertib, FOLFIRI, Bevacizumab - Metastatic Colorectal Cancer, CRC | Phase 2 | Active not recruiting | Cardiff Oncology | 110 | 2024-02-27 | 2026-06-16 |
Showing 20 of 56. Sign in to see all of them.
Colorectal Neoplasms (26) · Carcinoma, Non-Small-Cell Lung (12) · Neoplasms (9) · Pancreatic Neoplasms (8) · Colonic Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (5) · Carcinoma, Renal Cell (4) · Lung Neoplasms (4) · Melanoma (4) · Neoplasm Metastasis (4) · Triple Negative Breast Neoplasms (4) · Gastrointestinal Neoplasms (3) · Ovarian Neoplasms (3) · Rectal Neoplasms (3) · Recurrence (3)
Neoplasms by Site (33) · Neoplasms (28) · Digestive System Diseases (27) · Digestive System Neoplasms (27) · Colonic Diseases (26) · Gastrointestinal Diseases (26) · Intestinal Diseases (26) · Intestinal Neoplasms (26) · Rectal Diseases (26) · Gastrointestinal Neoplasms (23) · Neoplasms by Histologic Type (14) · Lung Diseases (13) · Respiratory Tract Diseases (13) · Respiratory Tract Neoplasms (13) · Thoracic Neoplasms (13)
Cetuximab (8) · Bevacizumab (5) · Fluorouracil (3) · Folfox protocol (3) · IFL protocol (3) · Irinotecan (3) · Leucovorin (3) · CB-839 (2) · Capecitabine (2) · Oxaliplatin (2) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · Aspirin (1) · Blood Component Removal (1) · CCT239065 (1)
Motus GI Medical Technologies Ltd (5) · A2 Biotherapeutics Inc. (4) · Revolution Medicines, Inc. (3) · Virginia Commonwealth University (3) · Calithera Biosciences, Inc (2) · Chinese University of Hong Kong (2) · Shanghai Henlius Biotech (2) · Aktis Oncology, Inc. (1) · Beijing University of Chinese Medicine (1) · Biomea Fusion Inc. (1) · C4 Therapeutics, Inc. (1) · Cardiff Oncology (1) · Cartography Biosciences (1) · Chang Gung Memorial Hospital (1) · Fudan University (1)
United States (29) · China (11) · Spain (4) · France (3) · Canada (2) · Germany (2) · Hong Kong (2) · Israel (2) · Netherlands (2) · South Korea (2) · Taiwan (2) · Australia (1) · Ghana (1) · Greece (1) · Italy (1)
John Welch, MD, PhD (2) · Carrie A. Miller, Ph.D, MPH (1) · Derek Jonker, MD (1) · Elena Garralda, MD, PhD (1) · Emil Kuriakose, MD (1) · Emily Kinsey, MD (1) · Eric Ng, MD (1) · Eric W Ng, MD, FAAP (1) · Erin Kobetz-Kerman, Phd, MPH (1) · Evelien Dekker, MD, PhD (1) · Farshid Dayyani, MD (1) · Gerrit A Meijer, MD, PhD (1) · Glenn Hanna, MD (1)
PMID 26584600, PMID 29996152, PMID 31228203, PMID 33439695, PMID 34162204, PMID 36306483, PMID 36503495, PMID 36613569, PMID 37835479, PMID 38103947, PMID 38321218, PMID 38346438, PMID 39388688, PMID 39475591, PMID 40056080, PMID 40148035, PMID 40521168, PMID 40523897, PMID 41037823, PMID 41918932